Keaau, HI, United States of America

Maile Skomp

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Elan Pharmaceuticals, Inc.. Active years: 2010.

USPTO Granted Patents = 1 

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2010

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Maile Skomp: Innovator in Alzheimer's Research

Introduction

Maile Skomp is a notable inventor based in Keaau, HI (US). She has made significant contributions to the field of Alzheimer's disease research. Her work focuses on understanding the mechanisms of cell death associated with amyloid β-protein.

Latest Patents

Maile Skomp holds a patent for her invention titled "Signaling intermediates in an in vitro model of Alzheimer's disease." This invention provides a novel human protein known as the FISH adaptor protein, which is involved in amyloid β-protein-mediated cell death. Additionally, the patent outlines methods for modulating this cell death using agents that interfere with the activity of the FISH adaptor protein. She has 1 patent to her name.

Career Highlights

Maile Skomp is currently associated with Elan Pharmaceuticals, Inc., where she continues her research and development efforts. Her work has been instrumental in advancing the understanding of Alzheimer's disease and potential therapeutic approaches.

Collaborations

Throughout her career, Maile has collaborated with esteemed colleagues, including Irene Griswold-Prenner and Sarah Wright. These collaborations have further enriched her research and contributed to the scientific community's knowledge of Alzheimer's disease.

Conclusion

Maile Skomp's innovative work in Alzheimer's research highlights her dedication to understanding and combating this devastating disease. Her contributions through her patent and collaborations reflect her commitment to advancing medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…